BRIAN HERB ANNEX
Medical Practice in Durham, NC
License number
Michigan 4301059471
Issued Date
Apr 23, 1992
Expiration Date
Jan 31, 1996
Category
Medicine
Type
Medical Doctor
Address
Address
Durham, NC 27705
Personal information
See more information about BRIAN HERB ANNEX at radaris.comName
Address
Phone
4820 Montvale Dr, Durham, NC 27705
4820 Montvale Dr, Durham, NC 27705
7120 Creek Wood Dr, Chapel Hill, NC 27514
Professional information
See more information about BRIAN HERB ANNEX at trustoria.com
Brian Annex, Lumberton NC
Brian Annex, Lumberton NC
Work:
Private Diagnostic Clinic
403 W 27Th St, Lumberton, NC 28358 University of Virginia Physicians Group
57 Beam Ln, Fishersville, VA 22939 University of Virginia
1215 Lee St, Charlottesville, VA 22908 Private Diagnostic Clinic
1000 Trent Dr, Durham, NC 27710
403 W 27Th St, Lumberton, NC 28358 University of Virginia Physicians Group
57 Beam Ln, Fishersville, VA 22939 University of Virginia
1215 Lee St, Charlottesville, VA 22908 Private Diagnostic Clinic
1000 Trent Dr, Durham, NC 27710
Method For Inducing Angiogenesis In A Heart Of A Patient
Method For Inducing Angiogenesis In A Heart Of A Patient
US Patent:
8178493, May 15, 2012
Filed:
Apr 6, 2009
Appl. No.:
12/419038
Inventors:
David T. Hung - Belmont CA, US
Brian H. Annex - Durham NC, US
Kevin P. Landolfo - Chapel Hill NC, US
W. Michael Kavanaugh - Mill Valley CA, US
Brian H. Annex - Durham NC, US
Kevin P. Landolfo - Chapel Hill NC, US
W. Michael Kavanaugh - Mill Valley CA, US
Assignee:
Novartis Vaccines and Diagnostics, Inc. - Emeryville CA
International Classification:
C07K 14/50, C07K 14/515, A61K 38/00
US Classification:
514 91, 514 133
Abstract:
The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i. e. , from about 5 ng to less than 135,000 ng) of an angiogenic agent.
Dose Of An Angiogenic Factor And Method Of Administering To Improve Myocardial Blood Flow
Dose Of An Angiogenic Factor And Method Of Administering To Improve Myocardial Blood Flow
US Patent:
2003017, Sep 11, 2003
Filed:
Mar 24, 2003
Appl. No.:
10/395541
Inventors:
David Hung - Belmont CA, US
Brian Annex - Durham NC, US
Kevin Landolfo - Chapel Hill NC, US
W. Kavanaugh - Mill Valley CA, US
Brian Annex - Durham NC, US
Kevin Landolfo - Chapel Hill NC, US
W. Kavanaugh - Mill Valley CA, US
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61K038/18
US Classification:
514/012000
Abstract:
The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent.
Dose Of An Angiogenic Factor And Method Of Administering To Improve Myocardial Blood Flow
Dose Of An Angiogenic Factor And Method Of Administering To Improve Myocardial Blood Flow
US Patent:
2006000, Jan 12, 2006
Filed:
Sep 6, 2005
Appl. No.:
11/220027
Inventors:
David Hung - Belmont CA, US
Brian Annex - Durham NC, US
Kevin Landolfo - Chapel Hill NC, US
W. Kavanaugh - Mill Valley CA, US
Brian Annex - Durham NC, US
Kevin Landolfo - Chapel Hill NC, US
W. Kavanaugh - Mill Valley CA, US
Assignee:
Chiron Corporation - Emeryville CA
Duke University - Durham NC
Duke University - Durham NC
International Classification:
A61K 38/18
US Classification:
514012000
Abstract:
The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent.
Method Of Treating Erectile Dysfunction
Method Of Treating Erectile Dysfunction
US Patent:
2004003, Feb 19, 2004
Filed:
Dec 10, 2002
Appl. No.:
10/315248
Inventors:
Craig Donatucci - Durham NC, US
Julie Miller - Clarksville MD, US
Brian Annex - Durham NC, US
Julie Miller - Clarksville MD, US
Brian Annex - Durham NC, US
International Classification:
A61K038/18
US Classification:
514/012000
Abstract:
The present invention relates, in general, to erectile dysfunction and, in particular to a method of treating or preventing dysfunction of penile, clitoral or vaginal erectile tissue by administering an angiogenic growth factor, such as vascular endothelial growth factor (VEGF), or active fragment thereof or mimetic thereof.